Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCB02A in CLDN18.2-positive Advanced Solid Tumors
NCT07460375Phase 2Recruiting
- Sponsor
- LigaChem Biosciences
- Start
- Oct 2026
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of LCB02A in solid tumor, sponsored by LigaChem Biosciences. Started Oct 2026; status: recruiting.
02
Drugs
LCB02A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07460375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460375.